Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6328144 | 1.00 | ENPP2 (0.34) | ENPP2TSHRMAPK1RECQLL3MBTL1 | |
| SCHEMBL6326637 | 0.89 | ALDH1A1 (0.34) | KDM4EALDH1A1PTGDR2GRM1 | |
| SCHEMBL6325414 | 0.89 | ALDH1A1 (0.34) | KDM4EALDH1A1PTGDR2GRM1 | |
| SCHEMBL8491832 | 0.79 | KMT2A (0.39) | TSHRMAPK1RECQLL3MBTL1KDM4E | |
| SCHEMBL8491834 | 0.79 | KMT2A (0.39) | TSHRMAPK1RECQLL3MBTL1KDM4E | |
| SCHEMBL6831342 | 0.77 | ALDH1A1 (0.34) | ENPP2MAPK1ALDH1A1PTGDR2 | |
| SCHEMBL6332863 | 0.77 | ALDH1A1 (0.34) | ENPP2MAPK1ALDH1A1PTGDR2 | |
| SCHEMBL6328700 | 0.75 | KDM4E (0.30) | KDM4EALDH1A1 | |
| SCHEMBL6328695 | 0.75 | KDM4E (0.30) | KDM4EALDH1A1 | |
| SCHEMBL8491740 | 0.74 | ESR1 (0.36) | ENPP2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936570-B2 | Tetrazolinone derivatives | NIHON BAYER AGROCHEM, K.K. (JP) | 2005-08-30 | — | — | US | disclosed |
| US-20040242895-A1 | Novel tetrazolinone derivatives | YANAGI AKIHIKO (JP) | 2004-12-02 | — | — | US | disclosed |
| US-6790810-B2 | Tetrazolinone derivatives | NIHON BAYER AGROCHEM K.K. (JP) | 2004-09-14 | — | — | US | disclosed |
| EP-1208090-A1 | HERBICIDALTETRAZOLINONE DERIVATIVES | NIHON BAYER AGROCHEM K.K. (JP) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001010850-A1 | HERBICIDAL TETRAZOLINONE DERIVATIVES | NIHON BAYER AGROCHEM K.K. (DE) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242895-A1 | Novel tetrazolinone derivatives | CBR3, CBR1, CYP1B1 | ENPP2 4242/4885TSHR 1295/4885MAPK1 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.